柔红霉素、阿糖胞苷(Ara-c)与尼洛替尼(TAsigna)联合方案(DATA)治疗KIT表达新诊断急性髓系白血病的II期研究
这项单臂II期双中心研究纳入34例KIT(CD117)表达的新诊断急性髓系白血病患者,中位年龄58.5岁,采用尼洛替尼联合7+3诱导(柔红霉素60 mg/m2)、大剂量阿糖胞苷巩固及2年维持治疗。21例(62%)达缓解,可评估患者完全缓解率78%;13例(38%)接受异基因造血干细胞移植,均存活。3级非血液学毒性常见(>20%)包括发热性中性粒细胞减少、低磷血症、肝酶升高和高血压;1例(3%)诱导期死于肝衰竭。
要点
- 34例KIT表达新诊断AML患者接受DATA方案,21例(62%)达缓解,可评估患者完全缓解率78%。
- 13例(38%)接受异基因造血干细胞移植,全部存活(100%)。
- 诱导期1例(3%)死于肝衰竭,认为继发于柔红霉素。
核心结论
- 本研究显示接受异基因造血干细胞移植的患者获得了良好结局,可能值得开展更大规模研究以在該特定人群中验证本研究发现。
研究设计与样本
- 单臂II期双中心研究,纳入34例KIT(CD117)表达的新诊断急性髓系白血病患者,中位年龄58.5岁。
- 治疗方案为尼洛替尼联合7+3诱导(柔红霉素60 mg/m2)、大剂量阿糖胞苷巩固,随后若患者适合则接受2年维持治疗。
- 必要时允许患者接受异基因造血干细胞移植(HCT)。
- 主要目标是提高联合方案的完全缓解率。
主要发现
- 34例患者中21例(62%)达缓解。
- 可评估患者的完全缓解率为78%。
- 34例中13例(38%)接受异基因造血干细胞移植,这13例全部存活(100%)。
- 常见(>20%)的3级非血液学毒性包括发热性中性粒细胞减少、低磷血症、肝酶升高和高血压。
- 仅1例患者(3%)在诱导期死于肝衰竭,认为继发于柔红霉素。
临床怎么用
- 原文结论未据此给出临床推荐。
局限性
- 原文在结论中提出可能值得开展更大规模研究以在該特定人群中验证本研究发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) is a challenging cancer in terms of achieving and maintaining long-duration remissions. Many novel therapies have been added to the standard regimen (combining cytarabine and anthracycline "7 + 3") to achieve such goals. Nilotinib is an oral multikinase inhibitor that is active against KIT tyrosine kinase, an important stem cell target. In this trial, we combined nilotinib with 7 + 3 induction (daunorubicin 60 mg/m2), high-dose cytarabine consolidation, and subsequently, if the patient was a candidate, for 2 years' maintenance therapy in patients with AML and KIT (CD117) expression. Patients were allowed to proceed to allogeneic hematopoietic cell transplantation (HCT) if deemed necessary. Our primary goal was increased complete remission rate with this combination. Thirty-four patients (with a median age 58.5 years) were enrolled on a single-arm phase II bi-institutional study; 21 (62%) patients achieved remission. The complete remission rate was 78% in evaluable patients. Thirteen of 34 (38%) patients had allogeneic HCT, all thirteen of which are still alive (100%). Common (>20%) grade 3 non-hematological toxicities included febrile neutropenia, hypophosphatemia, elevated liver enzymes, and hypertension. Only one patient (3%) died in induction due to liver failure, which was thought secondary to daunorubicin. Our current study reveals good outcomes in patients who received HCT and may warrant a larger study to confirm our findings in that specific population.
引用
- Al-Kali A, Tibes R, Atherton P, et al. A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression. Am J Hematol. 2023. PMID: 36625066. doi:10.1002/ajh.26831
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。